Physicochemical Properties
| Molecular Formula | C12H13CLN2O |
| Molecular Weight | 236.70 |
| Exact Mass | 236.072 |
| CAS # | 6028-07-5 |
| Related CAS # | 525-57-5 (Parent) |
| PubChem CID | 145825 |
| Appearance | Light yellow to yellow solid powder |
| Boiling Point | 507.5ºC at 760 mmHg |
| Melting Point | 265-268ºC (dec.) |
| Flash Point | 231ºC |
| LogP | 2.476 |
| Hydrogen Bond Donor Count | 3 |
| Hydrogen Bond Acceptor Count | 2 |
| Rotatable Bond Count | 0 |
| Heavy Atom Count | 16 |
| Complexity | 289 |
| Defined Atom Stereocenter Count | 0 |
| InChi Key | BSWAWVOHMZNXOS-UHFFFAOYSA-N |
| InChi Code | InChI=1S/C12H12N2O.ClH/c1-7-12-10(4-5-13-7)9-3-2-8(15)6-11(9)14-12;/h2-3,6,14-15H,4-5H2,1H3;1H |
| Chemical Name | 1-methyl-4,9-dihydro-3H-pyrido[3,4-b]indol-7-ol;hydrochloride |
| HS Tariff Code | 2934.99.9001 |
| Storage |
Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition | Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs) |
Biological Activity
| Targets | CYP1 |
| References |
[1]. Harmaline and harmalol inhibit the carcinogen-activating enzyme CYP1A1 via transcriptional and posttranslational mechanisms. Food Chem Toxicol. 2012;50(2):353-362. |
Solubility Data
| Solubility (In Vitro) | DMSO: 100 mg/mL (422.48 mM) |
| Solubility (In Vivo) |
Solubility in Formulation 1: 2.5 mg/mL (10.56 mM) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), suspension solution; with sonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: 2.5 mg/mL (10.56 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 3: 5 mg/mL (21.12 mM) in 50% PEG300 50% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 4: 2 mg/mL (8.45 mM) in 0.5% CMC-Na/saline water (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution.  (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.2248 mL | 21.1238 mL | 42.2476 mL | |
| 5 mM | 0.8450 mL | 4.2248 mL | 8.4495 mL | |
| 10 mM | 0.4225 mL | 2.1124 mL | 4.2248 mL |